A protocol for nitroglycerin (NTG) use based on experiences with regard to new and previously described obstetric cases is presented. The efficacy of NTG tocolysis for obstetric emergencies is clinically evaluated.
Clinical situations requiring prompt uterine relaxation include acute uterine inversion, [1] [2] [3] [4] uterine hyperstimulation, 5, 6 retained placenta, [7] [8] [9] [10] [11] [12] [13] difficult fetal extraction at vaginal or cesarean delivery, 2,8 -15 and version and extraction for multiple gestations. 13, 16, 17 The techniques generally available for tocolysis include the induction of general anesthesia and the parenteral administration of various tocolytic drugs. Due to limitations of these techniques and the reported success of nitroglycerin (NTG), we developed a protocol for acute tocolysis using intravenous (i.v.) NTG. Herein we report 22 new cases and discuss a protocol derived from our experience and a review of previously published cases. The efficacy and safety of NTG administered under protocol favor its use for acute tocolysis. However, attention to detail in administration and patient monitoring are essential to assure patient safety.
METHODS
The study was conducted at a tertiary care teaching hospital that performs ϳ5300 deliveries a year. During a 45-month study interval in which 18,765 deliveries occurred, 22 patients were chosen for acute NTG tocolysis by senior obstetricians in consultation with attending anesthesiologists. NTG administration was restricted to the operating room with a faculty anesthesiologist present. The indications for NTG treatment for hemodynamically stable parturients when acute uterine relaxation was clinically required included retained placenta (6 of 22, 27%), version and extraction of second twin (2 of 22, 9%), difficult fetal extraction during vaginal delivery (7 of 22, 32%) or cesarean delivery (7 of 22, 32%), and acute uterine inversion (1 of 22, 4%). Once the need for tocolysis was established and the hemodynamic stability of the parturient was assessed, an i.v. bolus of at least 500 ml of an isotonic salt solution (lactated Ringer's solution) was administered. The chosen dose of NTG was then diluted in normal saline (0.9% NaCl) to a concentration of 50 g/ml and administered through a freely flowing, large bore i.v. line. As discussed in detail later, an initial dose of 50 to 500 g of NTG was administered rapidly. The effects were judged by the obstetrician. Thereafter, additional bolus doses were administered at intervals of 60 to 90 seconds until clinically adequate uterine relaxation occurred or maternal hypotension developed. Hypotension was treated with increased i.v. hydration and titrated doses of parenteral ephedrine. A solution of oxytocin (20 to 40 international units) diluted in 1 liter of an isotonic salt solution was administered following the obstetric maneuver(s). If the return of uterine tone was judged to be either tardy or incomplete by the obstetrician, either 0.2 mg of methergine or 0.25 mg of 15-methyl prostaglandin F 2 ␣ (Hemabate) could be administered intramuscularly, in the absence of any known contraindication(s), and repeated at intervals of 10 to 30 minutes, as required. In all cases, the parturients were monitored with a transcutaneous oxygen saturation meter, a continuous electrocardiogram, and an automated blood pressure device.
After delivery, the medical records for both infant and parturient were reviewed and pertinent data were recorded. A MEDLINE search was conducted to identify previously published data concerning NTG Original Article
administered for obstetric emergencies. Dosing and outcome results from this total experience were tabulated and summarized.
RESULTS
Adequate uterine relaxation occurred in all 22 parturients (see Table  1 ), permitting successful obstetric maneuvers. The largest percent decrease in systolic arterial pressure from the originally observed baseline was 37% (patient 19); the mean systolic pressure decrease was 13.1 Ϯ 17.8 mm Hg. The largest percent decrease in diastolic arterial pressure from the originally observed baseline was 36% (patient 19); the mean diastolic pressure decrease was 9.5 Ϯ 12.6 mm Hg. Six patients (27%) received 10 to 30 mg of ephedrine in divided doses after NTG administration. No patients required neosynephrine to maintain arterial pressure. The greatest change in heart rate noted was an increase of 40%; the mean change in heart rate was 1. 
DISCUSSION
Prompt uterine relaxation can facilitate selected obstetric procedures. In the past, inhalation anesthesia was the principal method used for tocolysis. Although inhalation anesthetics provide insensitivity to pain and effective uterine relaxation, they cannot be rapidly administered. Furthermore, the potential risks of vomiting and aspiration 18 require endotracheal intubation. Due to these limitations, tocolytic drugs such as magnesium sulfate (MgSO 4 ) 19 -21 and the betamimetics 21, 22 are frequently chosen for acute uterine relaxation. However, these drugs have important limitations. MgSO 4 requires slow i.v. administration and has a 5-to 7-minute administration to response interval, 21 limiting true emergency use. The other major class of commonly used tocolytics, the betamimetics, are rapid in onset when administered parenterally, but their use risks cardiac dysrhythmias and other bothersome side effects. Other potentially effective drugs include the calcium channel blockers, oxytocin inhibitors, and the anti-prostaglandins. As yet, little data exist concerning the use of these drugs as acute uterine relaxants. As discussed below, the organic nitrate esters, and NTG in particular, are attractive alternatives to these traditionally used tocolytics.
In comparison with alternative tocolytic drugs and general anesthesia, NTG has several important advantages. NTG is physically stable in solution and is neither explosive nor flammable. The drug is lipid soluble and can be administered by the i.v., transdermal, oral, nasal, or sublingual route (Table 2 ). After i.v. administration, the tocolytic effect usually develops within Յ60 to 90 seconds with a peak at 90 to 120 seconds (see Table 2 ). Rapidly eliminated by hepatic metabolism, the effects of NTG persist for only 2 to 5 minutes, usually avoiding the need for reversal agents. This brief half-life also permits the drug to be titrated to response by repeated bolus administration. These properties help control the extent of tocolysis and limit the risk of complications. A potential limitation of NTG is its lack of analgesic effect. If pain relief is required, the concomitant administration of an analgesic drug or technique is necessary.
In the 22 new cases presented here, NTG doses ranging from 50 g to 500 g were noted to be safe and effective. Although declines in arterial pressure were occasionally observed, these were promptly and easily corrected and did not result in observed maternal or neonatal injury. There were no cases of uterine atony or hemorrhage directly associated with NTG administration. As reported in the literature, effective doses of parenteral NTG for uterine relaxation range from 50 g to 1850 g, with most investigators employing an initial dose of 100 to 500 g. Of the 207 procedures identified in our literature review (see Table 2 ), 143 used an initial dose of Ͻ400 g. Adequate uterine relaxation was reported to occur in all cases. The use of ephedrine (4.5 to 10 mg) was reported in only three cases to correct hypotension resulting from an initial dose of Ͻ400 g (Chan et al., 23 Bayhi et al., 3 Mercier and Benhamou
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One patient who received two doses of 50 g of NTG subsequently required a blood transfusion for excessive blood loss in a case complicated by a uterine inversion (Altabef et al. 4 ). Postpartum hemorrhage (Craig et al. 25 ) and hypotension (Chan et al., 23 Bayhi et al., 3 Mercier et al. 6 ) were more commonly observed in parturients receiving initial doses of Ͼ400 g NTG.
The published literature reports various modes of NTG administration. After some consideration, we chose to use the i.v. route, using a dilute NTG solution. I.v. NTG bolusing with limited incremental doses helps prevent overtreatment, and the i.v. line can be used for fluid and/or vasopressor administration, if required. A potential disadvantage to i.v. NTG administration is the need for dilution before use. An attractive alternative to i.v. dosing may be the use of the NTG metered dose sublingual spray (Redick and Livingston, 13 Greenspoon and Kovacic, 17 Dalton and Ray, 9 Craig et al., 25 Dawson and Gabbot 26 ). The dosing regimen for NTG depends on clinical circumstances. As a general rule, because hemorrhage and hypotension are associated with higher NTG doses, the minimal effective dose of NTG is best. In emergency situations in which rapid, reliable tocolysis is required, we recommend an initial dose of 250 to 500 g with the understanding that maternal hypotension is likely to result. In selected cases (such as retained placenta) in which an immediate response is not necessary, a lower initial dose is appropriate. In these less urgent cases, we recommend an initial NTG dose of 50 to 250 g to minimize the risk of maternal hypotension and hemorrhage. Regardless of the initial dose, our clinical experience supports repeat boluses of 50 to 250 g at 60-to 90-second intervals given until the desired effect is achieved, a total dose of 1000 g is reached, or hypotension is observed. Because the patients' physiological status is variable depending on the clinical setting and prior therapy, there are a wide range of responses with NTG, regardless of the initial dose. Thus, patients must be observed closely for effect and vital signs must be closely monitored. Although three of our patients with twin vaginal delivery received 50 g of NTG with apparent satisfactory tocolysis, we do not recommend relying on an initial dose of Ͻ250 g when rapid, reliable tocolysis is required.
In general, there are few and usually clinically insignificant maternal complications associated with acute NTG administration. Arterial blood pressure often decreases (see Tables 1 and 2 ) transiently. In our experience, normal pressure returns rapidly with discontinuation of the drug and the administration of i.v. fluid. Although ephedrine was administered in six cases, none of our patients required additional therapy to reverse the cardiovascular effects of NTG. Hypotension is more likely when the initial NTG dose is Ն400 g; however, as noted, a wide range of responses is observed. This probably reflects variations in vascular volume and the complex effects of polypharmacy that characterize specific cases. Due to the reduced venous tone and mesenteric and lower extremity blood pooling, when feasible we recommend positioning the parturient in slight Trendelenburg position in dorsal lithotomy with the legs elevated. This increases venous return to the central circulation and may help minimize hypotension and the resulting need for vasoactive drugs.
There are no data indicating that acute NTG dosing during pregnancy adversely affects the infant. David et al., 27 studied infants exposed to NTG during elective cesarean delivery with a controlled group and reported no significant differences in Apgar scores, median arterial umbilical cord pH, blood pressure, and pulse rates. In their report, the fetal:maternal ratio of NTG metabolites in plasma was only 1:160 at 5 minutes after a maternal infusion of 500 g of NTG. In another study, Hood et al. 28 infused NTG at a dose rate sufficient to drop the mean maternal arterial pressure by 20% to blunt the hypertensive response to endotracheal intubation. Again, no adverse effects were observed with regard to neonatal hemodynamics, Apgar scores, or umbilical cord gases.
Physiologically, NTG acts as a smooth muscle nitric oxide donor, which activates the cyclic guanosine monophosphate pathway involved in muscle relaxation. Smith and Brien 29 recently published a review of NTG in obstetric emergencies that includes a discussion of the proposed mechanism of NTG action as a nitric oxide donor to effect uterine relaxation.
All techniques for acute uterine relaxation involve risk. Safety and efficacy are prerequisites for the administration of any potent tocolytic. Not all clinical settings are appropriate for tocolysis, and careful patient selection is mandatory. In determining which agent to administer, the speed, efficacy, and side effects of the drug or technique and the maternal cardiovascular status needs consideration.
If i.v. NTG is chosen as an acute tocolytic, several precautions are prudent. The preliminary dilution of the drug, its rapid onset after administration, and its relatively short duration of action restrict its use to controlled circumstances in which close communication between the obstetrician and anesthesiologist as well as patient monitoring can be maintained. Before NTG is administered, the parturient should be hydrated and appropriately positioned to minimize the hypotensive response. The necessary equipment and personnel must be available for the treatment of hypotension, hemorrhage, and uterine atony.
To date, there are limited data on efficacy and/or safety comparing NTG with other potential tocolytic drugs and techniques. The clinical situations, such as retained placenta and uterine inversion, in which NTG is most likely to prove useful are both infrequent and unpredictable. We encountered an average of one case appropriate for acute NTG tocolysis for every 1025 live births. Due to the uncommon requirement for acute tocolysis and the complexity of many cases, a prospective trial comparing this agent against the other possible drugs (e.g., MgSO 4 , or the betamimetics) will be difficult. In light of the infrequency of cases appropriate for emergency tocolysis, a retrospective matched cohort analysis could be conducted to establish the perinatal risk associated with NTG compared with two or more other tocolytics. A number of clinical reports have found NTG to be a fast-acting, effective tocolytic (Dayan and Schwalbe, 1 Weiss and Diaz, 2 Altabef et al., 4 Bayhi et al., 3 Axemo et al., 8 Dalton and Ray, 9 Dessard et al., 10 Riley et al, 11 Redick and Livingston, 13 Wessen et al., 12 Peng et al., 7 ). 16,17,23-26,30 -32 The principal advantages of NTG in comparison with other commonly used tocolytic drugs are evident when prompt uterine relaxation is required. The speed of onset and the efficacy of NTG effect are not paralleled by other classes of available tocolytic drugs such as betamimetics or MgSO 4 . In our experience, consequential maternal complications are infrequently observed when appropriate cases for treatment are selected, treatment is restricted to the operating room, close attention to maternal cardiovascular support is provided, and experienced clinicians are present. The drug appears to have no direct adverse effects on the fetus. Despite the limitations of current data, the review of 207 reported cases of acute NTG tocolysis in widely differing dosing regimens and clinical settings is promising. NTG or similar organic nitrate compounds may prove to be the drug of choice for acute uterine relaxation.
